Selection and characterization of viruses resistant to the dual acting pyrimidinedione entry and non-nucleoside reverse transcriptase inhibitor IQP-0410

Antiviral Research

Volumn 100, Issue 2, 2013, Pages 382-391

  Buckheit, Robert W ^a   Watson Buckheit, Karen ^a   Sturdevant, Christa Buckheit ^b   Buckheit III, Robert W ^c  

^a ImQuest Biosciences   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

HIV; NNRTIs; Pyrimidinediones; Resistance

Indexed keywords

AMINO ACID; CD4 ANTIGEN; EFAVIRENZ; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; IQP 0410; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PYRIMIDINE DERIVATIVE; PYRIMIDINEDIONE; RNA DIRECTED DNA POLYMERASE; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS ENVELOPE PROTEIN;

ALLOSTERISM; ARTICLE; BINDING SITE; CELL CULTURE; CONFORMATION; CONTROLLED STUDY; CROSS RESISTANCE; DRUG EFFICACY; DRUG MECHANISM; GENE MUTATION; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HYDROPHOBICITY; IN VITRO SELECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; TARGET CELL; VIRUS CELL INTERACTION; VIRUS CHARACTERIZATION; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS RESISTANCE; VIRUS STRAIN; WILD TYPE; ANTIVIRAL RESISTANCE; DRUG EFFECT; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS; NNRTIS; NUCLEOTIDE SEQUENCE; PYRIMIDINEDIONES; RESISTANCE;

HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2;

HIV; NNRTIS; PYRIMIDINEDIONES; RESISTANCE;

ANTIVIRAL AGENTS; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, VIRAL; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV FUSION INHIBITORS; HIV REVERSE TRANSCRIPTASE; HIV-1; HIV-2; HUMANS; PYRIMIDINES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 84885348700     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2013.09.005     Document Type: Article

References (43)

1. J. Adams, N. Patel, N. Mankaryous, M. Tadros, and C.D. Miller Non-nucleoside reverse transcriptase inhibitor resistance and the role of the second-generation agents Ann. Pharmacother. 44 2010 157 165
2. M. Baba, H. Tanaka, E. De Clercq, R. Pauwels, J. Balzarini, D. Schols, H. Nakashima, C.F. Perno, R.T. Walker, and T. Miyasaka Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative Biochem. Biophys. Res. Commun. 165 1989 1375 1381
3. M. Baba, S. Shigeta, H. Tanaka, T. Miyasaka, M. Ubasawa, K. Umezu, R.T. Walker, R. Pauwels, and E. De Clercq Highly potent and selective inhibition of HIV-1 replication by 6-phenylthiouracil derivatives Antiviral Res. 17 1992 245 264
4. M. Baba, S. Shigeta, S. Yuasa, H. Takashima, K. Sekiya, M. Ubasawa, H. Tanaka, T. Miyasaka, R.T. Walker, and E. De Clercq Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro Antimicrob. Agents Chemother. 38 1994 688 692
5. A. Blas-Garcia, J.V. Esplugues, and N. Apostolova Twenty years of HIV-1 non-nucleoside reverse transcriptase inhibitors: time to reevaluate their toxicity Curr. Med. Chem. 18 2011 2186 2195
6. P.L. Boyer, M.J. Currens, J.B. McMahon, M.R. Boyd, and S.H. Hughes Analysis of non-nucleoside drug-resistant variants of human immunodeficiency virus type 1 reverse transcriptase J. Virol. 67 1993 2412 2420
7. R.W. Buckheit Jr., V. Fliakas-Boltz, W.D. Decker, J.L. Roberson, T.L. Stup, C.A. Pyle, E.L. White, J.B. McMahon, M.J. Currens, and M.R. Boyd Comparative anti-HIV evaluation of diverse HIV-1-specific reverse transcriptase inhibitor-resistant virus isolates demonstrates the existence of distinct phenotypic subgroups Antiviral Res. 26 1995 117 132
8. R.W. Buckheit Jr., V. Fliakas-Boltz, S. Yeagy-Bargo, O. Weislow, D.L. Mayers, P.L. Boyer, S.H. Hughes, B.C. Pan, S.H. Chu, and J.P. Bader Resistance to 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives is generated by mutations at multiple sites in the HIV-1 reverse transcriptase Virology 210 1995 186 193
9. R.W. Buckheit Jr., E.L. White, V. Fliakas-Boltz, J. Russell, T.L. Stup, T.L. Kinjerski, M.C. Osterling, A. Weigand, and J.P. Bader Unique anti-human immunodeficiency virus activities of the non-nucleoside reverse transcriptase inhibitors calanolide A, costatolide, and dihydrocostatolide Antimicrob. Agents Chemother. 43 1999 1827 1834
10. R.W. Buckheit Jr., K. Watson, V. Fliakas-Boltz, J. Russell, T.L. Loftus, M.C. Osterling, J.A. Turpin, L.A. Pallansch, E.L. White, J.W. Lee, S.H. Lee, J.W. Oh, H.S. Kwon, S.G. Chung, and E.H. Cho SJ-3366, a unique and highly potent non-nucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1) that also inhibits HIV-2 Antimicrob. Agents Chemother. 45 2001 393 400
11. R.W. Buckheit Jr., T.L. Hartman, K.M. Watson, H.S. Kwon, S.H. Lee, J.W. Lee, D.W. Kang, S.G. Chung, and E.H. Cho The structure-activity relationships of 2,4(1H,3H)-pyrimidinedione derivatives as potent HIV type 1 and type 2 inhibitors Antiviral Chem. Chemother. 18 2007 259 275
12. R.W. Buckheit Jr., T.L. Hartman, K.M. Watson, S.G. Chung, and E.H. Cho Comparative evaluation of the inhibitory activities of a series of pyrimidinedione congeners that inhibit human immunodeficiency virus types 1 and 2 Antimicrob. Agents Chemother. 52 2008 225 236
13. P.A. Cane New developments in HIV drug resistance J. Antimicrob. Chemother. 64 Suppl. 1 2009 i37 40
14. K.A. Cohen, J. Hopkins, R.H. Ingraham, C. Pargellis, J.C. Wu, D.E. Palladino, P. Kinkade, T.C. Warren, S. Rogers, and J. Adams Characterization of the binding site for nevirapine (BI-RG-587), a non-nucleoside inhibitor of human immunodeficiency virus type-1 reverse transcriptase J. Biol. Chem. 266 1991 14670 14674
15. J.H. Condra, E.A. Emini, L. Gotlib, D.J. Graham, A.J. Schlabach, J.A. Wolfgang, R.J. Colonno, and V.V. Sardana Identification of the human immunodeficiency virus reverse transcriptase residues that contribute to the activity of diverse non-nucleoside inhibitors Antimicrob. Agents Chemother. 36 1992 1441 1446
16. K. Danel, E. Larsen, E.B. Pedersen, B.F. Vestergaard, and C. Nielsen Synthesis and potent anti-HIV-1 activity of novel 6-benzyluracil analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine J. Med. Chem. 39 1996 2427 2431
17. M.P. de Bethune Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989-2009) Antiviral Res. 85 2010 75 90
18. J. Ding, K. Das, C. Tantillo, W. Zhang, A.D. Clark Jr., S. Jessen, X. Lu, Y. Hsiou, A. Jacobo-Molina, and K. Andries Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor alpha-APA R 95845 at 2.8 Å resolution Structure 3 1995 365 379
19. P.P. Fulco, and I.R. McNicholl Etravirine and rilpivirine: non-nucleoside reverse transcriptase inhibitors with activity against human immunodeficiency virus type 1 strains resistant to previous non-nucleoside agents Pharmacotherapy 29 2009 281 294
20. J. Gathe Jr. Adherence and potency with antiretroviral therapy: a combination for success J. Acquir. Immune Defic. Syndr. 34 Suppl. 2 2003 S118 122
21. P.M. Grob, J.C. Wu, K.A. Cohen, R.H. Ingraham, C.K. Shih, K.D. Hargrave, T.L. McTague, and V.J. Merluzzi Non-nucleoside inhibitors of HIV-1 reverse transcriptase: nevirapine as a prototype drug AIDS Res. Hum. Retroviruses 8 1992 145 152
22. T.L. Hartman, L. Yang, and R.J. Buckheit Antiviral interactions of combinations of highly potent 2,4 (1H, 3H)-pyrimidinedione congeners and other anti-HIV agents Antiviral Res. 92 2011 505 508
23. J. Kimpton, and M. Emerman Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene J. Virol. 66 1992 2232 2239
24. L.A. Kohlstaedt, J. Wang, J.M. Friedman, P.A. Rice, and T.A. Steitz Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor Science 256 1992 1783 1790
25. A. Mai, M. Artico, G. Sbardella, S. Massa, E. Novellino, G. Greco, A.G. Loi, E. Tramontano, M.E. Marongiu, and P. La Colla 5-Alkyl-2-(alkylthio)-6-(2,6- dihalophenylmethyl)-3, 4-dihydropyrimidin-4(3H)-ones: novel potent and selective dihydro-alkoxy-benzyl-oxopyrimidine derivatives J. Med. Chem. 42 1999 619 627
26. J.B. McMahon, M.J. Currens, R.J. Gulakowski, R.W. Buckheit Jr., C. Lackman-Smith, Y.F. Hallock, and M.R. Boyd Michellamine B, a novel plant alkaloid, inhibits human immunodeficiency virus-induced cell killing by at least two distinct mechanisms Antimicrob. Agents Chemother. 39 1995 484 488
27. J. Mellors, B. Larder, and R. Schinazi Mutations in HIV-1 reverse transcriptase and protease associated with drug resistance Int. Antivir. News 3 1995 8 13
28. A. Milinkovic, and E. Martinez Nevirapine in the treatment of HIV Expert Rev. Anti Infect. Ther. 2 2004 367 373
29. T. Miyasaka, H. Tanaka, M. Baba, H. Hayakawa, R.T. Walker, J. Balzarini, and E. De Clercq A novel lead for specific anti-HIV-1 agents: 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine J. Med. Chem. 32 1989 2507 2509
30. P.L. Nara, W.C. Hatch, N.M. Dunlop, W.G. Robey, L.O. Arthur, M.A. Gonda, and P.J. Fischinger Simple, rapid, quantitative, syncytium-forming microassay for the detection of human immunodeficiency virus neutralizing antibody AIDS Res. Hum. Retroviruses 3 1987 283 302
31. L. Palmisano, and S. Vella A brief history of antiretroviral therapy of HIV infection: success and challenges Ann. Ist. Super. Sanita. 47 2011 44 48
32. M. Popovic, M.G. Sarngadharan, E. Read, and R.C. Gallo Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS Science 224 1984 497 500
33. S. Portsmouth, J. Stebbing, and B. Gazzard Current treatment of HIV infection Curr. Top. Med. Chem. 3 2003 1458 1466
34. D.G. Prajapati, R. Ramajayam, M.R. Yadav, and R. Giridhar The search for potent, small molecule NNRTIs: A review Bioorg. Med. Chem. 17 2009 5744 5762
35. D.L. Romero, R.A. Olmsted, T.J. Poel, R.A. Morge, C. Biles, B.J. Keiser, L.A. Kopta, J.M. Friis, J.D. Hosley, K.J. Stefanski, D.G. Wishka, D.B. Evans, J. Morris, R.G. Stehle, S.K. Sharma, Y. Yagi, R.L. Voorman, W.J. Adams, W.G. Tarpley, and R.C. Thomas Targeting delavirdine/atevirdine resistant HIV-1: identification of (alkylamino)piperidine-containing bis(heteroaryl)piperazines as broad spectrum HIV-1 reverse transcriptase inhibitors J. Med. Chem. 39 1996 3769 3789
36. M.S. Saag, E.A. Emini, O.L. Laskin, J. Douglas, W.I. Lapidus, W.A. Schleif, R.J. Whitley, C. Hildebrand, V.W. Byrnes, and J.C. Kappes A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. L-697,661 working group N. Engl. J. Med. 329 1993 1065 1072
37. Z.K. Sweeney, and K. Klumpp Improving non-nucleoside reverse transcriptase inhibitors for first-line treatment of HIV infection: the development pipeline and recent clinical data Curr. Opin. Drug Discov. Devel. 11 2008 458 470
38. H. Tanaka, M. Baba, M. Ubasawa, H. Takashima, K. Sekiya, I. Nitta, S. Shigeta, R.T. Walker, E. De Clercq, and T. Miyasaka Synthesis and anti-HIV activity of 2-, 3-, and 4-substituted analogues of 1-[(2-hydroxyethoxy)methyl]- 6-(phenylthio)thymine (HEPT) J. Med. Chem. 34 1991 1394 1399
39. J. Vingerhoets, H. Azijn, E. Fransen, I. De Baere, L. Smeulders, D. Jochmans, K. Andries, R. Pauwels, and M.P. de Bethune TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments J. Virol. 79 2005 12773 12782
40. K. Watson Buckheit, L. Yang, and R.W. Buckheit Jr. Development of dual-acting pyrimidinediones as novel and highly potent topical anti-HIV microbicides Antimicrob. Agents Chemother. 55 2011 5243 5254
41. S.D. Young, S.F. Britcher, L.O. Tran, L.S. Payne, W.C. Lumma, T.A. Lyle, J.R. Huff, P.S. Anderson, D.B. Olsen, and S.S. Carroll L-743, 726 (DMP-266): a novel, highly potent non-nucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase Antimicrob. Agents Chemother. 39 1995 2602 2605
42. P. Zhan, X. Liu, and Z. Li Recent advances in the discovery and development of novel HIV-1 NNRTI platforms: 2006-2008 update Curr. Med. Chem. 16 2009 2876 2889
43. P. Zhan, X. Liu, Z. Li, C. Pannecouque, and E. De Clercq Design strategies of novel NNRTIs to overcome drug resistance Curr. Med. Chem. 16 2009 3903 3917